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Abstract
Background: An effective adaptive immune response requires activation of specific CD4 T cells. The capacity of B
cells to activate CD4 T cells in human cutaneous leishmaniasis caused by Leishmania (Viannia) has not been
evaluated.
Methods: CD4 T cell activation by B cells of cutaneous leishmaniasis patients was evaluated by culture of PBMCs or
purified B cells and CD4 T cells with Leishmania panamensis antigens. CD4 T cell and B cell activation markers were
evaluated by flow cytometry and 13 cytokines were measured in supernatants with a bead-based capture assay.
The effect of Leishmania antigens on BCR-mediated endocytosis of ovalbumin was evaluated in the Ramos human
B cell line by targeting the antigen with anti-IgM-biotin and anti-biotin-ovalbumin-FITC.
Results: Culture of PBMCs from cutaneous leishmaniasis patients with Leishmania antigens resulted in upregulation
of the activation markers CD25 and CD69 as well as increased frequency of CD25hiCD127− cells among CD4 T cells.
Concomitantly, B cells upregulated the costimulatory molecule CD86. These changes were not observed in PBMCs
from healthy subjects, indicating participation of Leishmania-specific lymphocytes expanded in vivo. Purified B cells
from these patients, when interacting with purified CD4 T cells and Leishmania antigens, were capable of inducing
significant increases in CD25 and CD69 expression and CD25hiCD127− frequency in CD4 T cells. These changes
were associated with upregulation of CD86 in B cells. Comparison of changes in CD4 T cell activation parameters
between PBMC and B cell/CD4 T cell cultures showed no statistically significant differences; further, significant
secretion of IFN-γ, TNF-α, IL-6 and IL-13 was induced in both types of cultures. Additionally, culture with Leishmania
antigens enhanced BCR-mediated endocytosis of ovalbumin in Ramos human B cells.
Conclusions: The capacity of B cells specific for Leishmania antigens in peripheral blood of cutaneous leishmaniasis
patients to activate CD4 T cells and induce cytokine secretion is similar to that of all cell populations present in
PBMCs. This capacity implicates B cells as a plausible target for modulation of the immune response to Leishmania
infection as a therapeutic strategy.
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Background
Leishmaniasis is a parasitic disease endemic in 88 countries
that affects an estimated 12 million people in the rural areas
of the tropical and subtropical regions of the world. In
South America, Leishmania species of the Viannia sub-
genus cause cutaneous and muco-cutaneous disease that
can become chronic and cause severe disfigurement. In
spite of the advances in knowledge of parasite biology and
the host immune response, effective and safe treatment re-
mains a challenge and there is yet no approved vaccine
[1,2]. These needs may be addressed by manipulating
the host immune response to obtain parasite elimination
without tissue damage.
Professional antigen presenting cells (APCs) initiate
the adaptive immune response by activating CD4 T cells.
Activation of APCs, in the form of MHCII molecule
upregulation and costimulatory molecule expression, is
essential for induction of immunity, and the cytokines
secreted during antigen presentation shape the ensuing
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response. In the murine model of cutaneous leishmaniasis
(CL) caused by L. major, IL-12 secretion by APCs is cru-
cial for generation of IFN-γ-secreting Th1 cells, macro-
phage activation and parasite elimination [3]. Failure to
generate a Th1 response leads to chronic disease. In the
human disease caused by L. (Viannia), cells from patients
with chronic disease secrete large amounts of IFN-γ
and TNF-α but also Th2 and regulatory cytokines such
as IL-13 and IL-10, resulting in an unbalanced immune
response, excessive inflammation, tissue damage, and
parasite survival [4-8]. A similar picture was observed
in a murine model of chronic L. (V.) panamensis infection
where IL-13 was shown to be crucial for development of
pathology [4]. Since CD4 T cell activation by APCs leads
to this harmful response, modulation of this event could
promote healing or prevent disease.
Three types of APCs are recognized: dendritic cells
(DCs), macrophages and B cells. As the natural host of
Leishmania, macrophages would be the ideal candidates
for initiating the adaptive immune response in CL. How-
ever, it is well documented that infection of macrophages
with Leishmania does not induce MHCII molecule upreg-
ulation, costimulatory molecule expression or IL-12 secre-
tion, but rather inhibits these processes, shutting down
antigen presentation by macrophages. These effects have
been shown in a range of Leishmania species in both ani-
mal models and human cells [9-12]. On the other hand,
DC function has been more difficult to determine, as both
activation and inhibition of APC function have been
found. In the murine L. major model it is well recognized
that DCs initiate the immune response and secrete IL-12
in the resistant phenotype [13]. However, studies with
other Leishmania species have shown that infection with
parasites does not lead to DC activation [14-18]. Notably,
L. (V.) braziliensis infection of DCs inhibits cell activation
and antigen presentation while uninfected neighboring
DCs are able to upregulate MHCII and costimulatory
molecules and induce T cell activation [18]. Thus, it
seems that induction of immunity by DCs in CL de-
pends on their avoidance of infection. In summary, both
macrophage and DC APC function can be inhibited by
L. (Viannia). Therefore, the participation of B cells in
CD4 T cell activation in CL caused by species of this
subgenus may be crucial.
The role of B cells in human CL caused by L. (Viannia)
has not been defined. Histological studies in Colombian
patients infected with L. (Viannia) have revealed promin-
ent B cell infiltration of skin lesions and leishmanin skin
test reaction sites [19,20], and a study from Brazil showed
a significant increase in B cell frequency in lymph node
aspirates of patients that presented lymphadenopathies
associated with the late stage of lesion development
[21]. These findings suggest that B cells may play an im-
portant role in the immune response to L. (Viannia). In
mice, lesion development caused by L. panamensis was
found to be delayed in the absence of B cells, although
final lesion size and parasite load were not affected [4].
B cells have been shown in murine models of leishman-
iasis to contribute to immunologic regulation through
production of cytokines and immunoglobulins and as a
result of antigen presentation [22-29]. However, vari-
ation occurs that may depend upon the species, specific
Leishmania strain and mouse genetics [27,29].
The contribution of B cells in CD4 T cell activation in
human CL or its pathogenesis is yet unexplored. B cells
specific for a particular antigen have an exquisite capacity
to concentrate and direct the antigen to the appropriate
processing compartments. Furthermore, BCR signaling in-
duces optimal APC activation, making B cells competent
APCs capable of activating naïve CD4 T cells. Hence,
the participation of B cells as APCs has been shown to
be essential in many different contexts [30-35]. Further-
more, their capacity to secrete several cytokines capable
of inducing Th1, Th2 and regulatory responses has been
well documented [36]. For these reasons, and in order
to identify immunomodulatory intervention strategies
we have examined the capacity of B cells to activate
CD4 T cells in CL.
In the present study, CD4 T cell activation by B cells
was assessed in cells from patients with CL caused by
L. (Viannia) species. We found that B cells upregulated
the costimulatory molecule CD86 in PBMC cultures stim-
ulated with L. panamensis and were able to activate CD4
T cells and induce cytokine secretion in the absence of
other recognized APCs. Furthermore, we show that expos-
ure to L. panamensis antigen enhances BCR-mediated
endocytosis by the Ramos human B cell line. Taken to-
gether these results indicate a role for B cells in the
modulating the immune response to L. panamensis.
Methods
Study design
We evaluated the response of cells from CL patients
from the southwestern region of Colombia where most
cases are caused by L. panamensis or L. braziliensis. We
have previously shown that there is a strong recall re-
sponse to L. panamensis antigens in patients from this re-
gion regardless of the infecting species [37-39]. Thus, we
stimulated cells with promastigote L. panamensis antigen
(pLAg) obtained from L. panamensis strain MHOM/
COL/81/L13. First, we compared CD4 T cell and APC
activation in CL patients and healthy subjects by cultur-
ing PBMCs with pLAg and measuring CD4 T cell, B cell
and DC activation markers. We then determined the
competence of B cells for CD4 T cell activation by cul-
turing them with CD4 T cells and pLAg and evaluating
activation of both cell types. We evaluated the cytokine
secretion profile of PBMC and B cell/CD4 T cell cultures
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to establish whether the cytokine profile induced by B
cell-CD4 T cell interaction is similar to that induced when
all PBMCs participate. Finally, we examined the effects
of exposure to pLAg on a human B cell line in relation
with induction of activation markers and BCR-mediated
endocytosis.
Human subjects and cells
Peripheral blood samples (60 to 100 mL) were obtained
from CL patients from the southwestern region of
Colombia (Departments of Valle del Cauca and Nariño).
Participants included 8 males and 2 females of 20 to
65 years of age (median = 27), who had typical cutaneous
lesions, were parasitologically diagnosed by smear, cul-
ture or biopsy, and had not received anti-leishmanial
treatment before enrollment. Blood samples from four
healthy subjects from non-endemic areas were obtained
as controls. All subjects had negative serology for HIV
and HTLV-1. All participants provided written informed
consent. The study protocol, consent forms and all pro-
cedures were approved by the CIDEIM Institutional Re-
view Board for the ethical conduct of research involving
human subjects.
PBMCs were isolated by centrifugation over Histopaque-
1077 (Sigma-Aldrich, St. Louis, MO). B cells and CD4 T
cells were isolated by MACS using the B cell isolation
and CD4+ T cell isolation kits II, respectively (Miltenyi
Biotec, Bergisch-Gladbach, Germany) following the manu-
facturer’s instructions. Purity assessed by staining with
anti-CD20 or anti-CD4 was ≥95% for both populations.
Ramos cells were obtained from the American Type
Culture Collection (Rockville, MD).
Cell culture
pLAg was prepared by suspending promastigotes of
the L. panamensis strain MHOM/COL/81/L13 at a
concentration of 1 × 107 parasites/mL, freezing in liquid
nitrogen and thawing at 37°C four times. Cells were sus-
pended in RMPI 1640 (Sigma-Aldrich) with 10% FBS
(Gibco, Carlsbad, CA), 2 mM L-glutamine, penicillin
(100 U/mL) and streptomycin (100 mg/mL) and distrib-
uted in 96 well plates in 200 μL per well. For PBMC
cultures, 4 × 105 PBMCs and for B cell/CD4 T cell co-
cultures, 2 × 105 B cells or 2 × 105 T cells or both cell
types were plated per well. Then 8 μL of pLAg were
added to the appropriate wells to reach a parasite:cell ratio
of 0.2:1. The cells were incubated for 5 days at 37°C with
5% CO2. Cells and supernatants were harvested for
evaluation of cell surface markers and cytokine secre-
tion, respectively.
Ramos cells were cultured in RPMI 1640 with 10% heat-
inactivated FBS at a concentration of 106 cells/mL with
pLAg (107 parasites/mL final concentration), 5 μM CpG
ODN 2006 (InvivoGen, San Diego, CA) or no stimulus for
48 hours. Cells were harvested for evaluation of cell
surface markers or BCR-mediated endocytosis.
Endocytosis assay
Ramos cells were incubated with goat F(ab’)2 anti-human
IgM-biotin (Invitrogen, Camarillo, CA) at 4°C for 20
minutes, washed twice with PBS, resuspended in media
and incubated with the Ova Antigen Delivery Reagent
(Ova-FITC conjugated to an anti-biotin antibody, Miltenyi
Biotec, Bergisch-Gladbach, Germany) at 37°C for different
time periods, at which cells were harvested and fluores-
cence evaluated by flow cytometry.
Flow cytometry
The following antibodies were used for cell surface marker
evaluation: anti-CD4-PE-Cy5, anti-CD69-PE, anti-CD127-
PE-Cy7, anti-CD20-PE-Cy7, anti-CD86-PE, anti-CD80-FITC
(eBioscience, San Diego, CA), anti-CD25-ECD, anti-HLA-
DR-ECD, and anti-CD11c-PC5 (Beckman Coulter, Brea,
CA). Primary human cells or Ramos cells were suspended
in FACS buffer (1× PBS, 1% BSA, 0.1% NaN3) and incu-
bated for 20 minutes with panels of the indicated anti-
bodies at 4°C. After washing, cells were analyzed in a
Navios flow cytometer (Beckman Coulter, Brea, CA) and
data was analyzed using FlowJo 7.6 software (Tree Star,
Inc., Ashland, OR). Gates used for analysis were set using
appropriate isotype controls.
Cytokine measurement
Cytokines were measured in culture supernatants using
the Human Th1/Th2/Th9/Th17/Th22 13plex FlowCyto-
mix Multiplex (eBioscience) following the manufacturer’s
instructions. Data were analyzed using FlowCytomix Pro
Software (eBioscience).
Statistical analysis
The Kolmogorov-Smirnov test was used to determine
parametric or non-parametric distribution of the data.
Thereafter, for comparisons between healthy subjects
and CL patients, parametric data were analyzed using
student t-test, and the Mann–Whitney test was applied
for non-parametric data. For comparisons between CL
patient cell cultures with L. panamensis- and control
cultures, parametric and non-parametric data were ana-
lyzed using the paired t-test and the Wilcoxon signed-
rank test, respectively. Statistical significance was defined
as p < 0.05. All data were analyzed using Prism 5 software
(GraphPad Software, Inc., La Jolla, CA).
Results and discussion
CD4 T cells and B cells of CL patients are concomitantly
activated by L. panamensis in PBMC cultures
We have previously shown that L. panamensis antigens
induce CD4 T cell proliferation and cytokine secretion
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in vitro in CL patients and that immune response profiles
differ in relation with clinical outcome; further, responses
are specific in that no response to pLAg is observed with
cells from uninfected individuals [5,38,40]. To determine
whether B cells contribute to CD4 T cell activation in the
context of active disease, we evaluated the activation of
both CD4 T cells and B cells by Leishmania antigens in
PBMC cultures. We found that the activation markers
CD25 and CD69 were upregulated in CD4+ lymphocytes
after incubation with pLAg (Figure 1A and B) and that
CD4 T cells with the CD25hiCD127− regulatory phenotype
were induced by re-exposure to parasite antigens in vitro
(Figure 1A and B). We have previously shown that cells
with this regulatory phenotype are increased after treat-
ment of chronic CL in patients from this region [38].
PBMCs from healthy subjects exposed to pLAg showed
no activation marker upregulation or increase in the
frequency of CD25hiCD127− cells (Figure 1B). Thus, the
changes in activation/regulatory markers observed in
cells from CL patients likely represent the re-activation
or expansion of cells specific for Leishmania antigens
that were primed in vivo.
To evaluate the potential of B cells as APCs in these
cultures, we evaluated the expression of the costimulatory
molecules CD86 and CD80 and MHCII molecules (HLA-
DR) in B cells (identified as CD20+ lymphocytes) com-
pared to DCs (identified as CD11chiFShi cells), recognized
APCs and potent inducers of the adaptive immune re-
sponse. As shown in Figure 2A, after 5 days of culture
without antigen, DCs showed higher expression of CD86
and HLA-DR than B cells. However, when incubated with
pLAg, B cells showed strong upregulation of CD86, while
CD80 and HLA-DR underwent no significant changes.
Meanwhile, DCs upregulated CD86 to a lesser extent and
showed strong upregulation of CD80, but HLA-DR was
downregulated (Figure 2). Exposure of cells from healthy
subjects to pLAg did not result in significant changes,
indicating that priming of cells in vivo was necessary for
the observed activation (Figure 2). These results show
that B cells specific for Leishmania antigens present in
the blood of CL patients are able to attain the costimu-
latory activities needed for antigen presentation while
maintaining MHCII expression. DCs upregulated costi-
mulatory molecules but presented a significant decrease
Figure 1 Stimulation with pLAg induces upregulation of activation/regulatory markers in CD4 T cells from CL patients. PBMCs were
isolated from peripheral blood of CL patients (n = 10) and healthy subjects (n = 4), incubated with promastigote L. panamensis antigen (pLAg) for
5 days and stained for CD4, CD25, CD127, and CD69. A. Contour plots of cells within the CD4+ lymphocyte gate from one representative CL patient
showing the effects of pLAg on the expression of CD25, CD127, and CD69. B. Expression of CD25 and CD69, and percentage of CD25hiCD127− cells
within the CD4+ gate for healthy subjects and CL patients. **p < 0.01.
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of MHCII expression after interaction with L. panamensis
antigens. Even though several reports show downregula-
tion of MHCII molecules after Leishmania infection in
both DCs [18,41,42] and macrophages [10,13,43], we are
not aware of any studies showing MHCII downregulation
in DCs after incubation with soluble Leishmania antigens.
Despite this decrease of MHCII, high expression of these
molecules was still evident in DCs, indicating that this cell
type was also poised to be a competent APC. Since both
CD80 and CD86 have been shown to be able to provide
the costimulation needed for CD4 T cell activation [44,45],
these results allow us to conclude that in these cultures
both B cells and DCs had a profile consistent with APC
activation.
To establish the cytokine profile induced by L. panamensis
in PBMCs from CL patients, we measured 13 cytokines
in culture supernatants. We found that incubation with
pLAg induced significant levels of IFN-γ, TNF-α, IL-13
and IL-6 (Figure 3). The cytokines IL-10, IL-12p70, IL-
1β, IL-5 and IL-9 were secreted in lower quantities, yet
the increase was statistically significant in relation to
controls. No significant production of IL-2, IL-17A, IL-4 or
IL-22 was induced (Figure 3). This cytokine profile,
which includes pro-inflammatory, Th1, Th2 and regulatory
Figure 2 Stimulation with pLAg induces upregulation of costimulatory molecules in APCs from CL patients. PBMCs were isolated from
peripheral blood of CL patients (CLP, n = 10) and healthy subjects (HS, n = 4), incubated with promastigote L. panamensis antigen (pLAg) for
5 days and stained for CD20, CD11c, CD86, CD80 and HLA-DR. A. Histograms of cells within the CD20+ lymphocyte gate (B cells, top panels) and
CD11chiFShi gate (DCs, bottom panels) from representative HS and CLP showing the effects of pLAg on expression of CD86, CD80 and HLA-DR.
B. Percentages of variation in mean fluorescence intensity (MFI) of each marker in cells incubated with pLAg in relation to controls for HS and
CLP. **p < 0.01, ***p < 0.001.
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cytokines, is consistent with previous studies of patients
from this region [4-8].
Purified B cells are capable of activating CD4 T cells and
inducing cells with a regulatory phenotype in the
absence of other APCs
The parallel activation of antigen-specific B cells and
CD4 T cells in CL patients suggested that B cells may be
able to induce CD4 T cell activation. To test this hypoth-
esis, B cells and CD4 T cells purified from PBMCs of CL
patients were stimulated with pLAg. CD25 and CD69
expression were significantly increased in CD4 T cells
when incubated with B cells and pLAg in relation to cells
cultured without antigen, or CD4 T cells incubated in the
absence of B cells, with or without pLAg (Figure 4A, B
and C). Although a trend of increased CD69 expression
was observed for naïve T cells in the presence of pLAg,
this increase was not significant (p = 0.08). Induction of
CD25hiCD127− CD4 T cells was also observed after in-
cubation with B cells and pLAg and was not evident
when either antigen or B cells were absent from cultures
(Figure 4A and D). A paired analysis of the net induc-
tion of the evaluated CD4 T cell activation parameters
in PBMC or purified B cell/CD4 T cell cultures did not
reveal statistically significant differences, corroborating
the comparable activation of CD4 T cells by Leishmania
specific B cells and PBMCs from CL patients (data not
shown).
To evaluate B cell activation in the B cell/CD4 T cell
co-cultures, we analyzed CD86, CD80 and HLA-DR ex-
pression. pLAg did not activate B cells in the absence of
CD4 T cells, but strong CD86 upregulation was induced
when CD4 T cells and pLAg were present (Figure 5A).
In concurrence with the PBMC cultures, addition of pLAg
to purified B cell/CD4 T cells did not result in CD80 or
HLA-DR upregulation (Figure 5B and C). These results
Figure 3 Stimulation with pLAg induces cytokine secretion in PBMCs from CL patients. PBMCs were isolated from peripheral blood of CL
patients (n = 10), incubated with promastigote L. panamensis antigen (pLAg) for 5 days and the indicated cytokines were measured in supernatants
with a bead-based assay. *p < 0.05, **p < 0.01.
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demonstrate that to become competent CD4 activating
cells, B cells require the presence of CD4 T cells. This
likely reflects the need for costimulatory ligands expressed
by activated CD4 T cells such as CD154 and cytokines
[31,32]. We also determined the cytokine profile induced
by L. panamensis antigens in B cell/CD4 T cell co-
cultures. pLAg induced significant secretion of IFN-γ,
TNF-α, IL-6, IL-13, IL-5, IL-9, IL-10 and IL-2, while no
significant amounts of IL-12p70, IL-1β, IL-17A, IL-4 or
IL-22 were detected (Figure 6). Importantly, no signifi-
cant secretion of any cytokine was observed when either
CD4 T cells or B cells were incubated alone with pLAg
(Figure 6).
These results demonstrate that the capacity of isolated
B cells from CL patients to activate CD4 T cells is simi-
lar to that of all APCs present in PBMCs. We performed
a paired analysis to compare the net increase for each
CD4 T cell activation parameter between PBMC and B
cell/CD4 T cell cultures and found no significant differ-
ences. Likewise, net cytokine secretion did not reveal
significant differences except for IL-12p70 and IL-1β
(which were secreted in low albeit significant amounts
only in PBMC cultures), IL-6 (which was secreted in
both types of cultures but in significant larger amounts
in PBMC cultures) and IL-2 (which was only secreted in
B cell/CD4 T cell cultures). Thus, 10 of the 13 cytokines
Figure 4 Purified B cells induce CD4 T cell activation in CL patients. B cells and CD4 T cells were purified from PBMCs of CL patients (n = 10),
incubated for 5 days separately or together, with or without promastigote L. panamensis antigen (pLAg), and stained for CD4, CD25, CD127, and
CD69. A. Representative plots for each culture condition showing the expression of CD25, CD127 and CD69 in the CD4+ gate. B. Expression of
CD25 within the CD4+ gate. C. Expression of CD69 within the CD4+ gate. D. Percentage of CD25hiCD127− cells within the CD4+ gate. *p < 0.05,
**p < 0.01, ***p < 0.001.
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measured had similar levels in both types of cultures in
spite of the fact that PBMCs contain several cytokine-
producing cell types besides B cells and CD4 T cells. The
differences observed in IL-12p70, IL-1β and IL-6 can be
explained by the presence of mononuclear phagocytes in
PBMCs that are known sources of these cytokines. Signifi-
cant IL-2 production only in B cell/CD4 T cell cultures
suggests that secretion of this cytokine is efficiently in-
duced by interaction of these cell types.
The known mechanisms for CD4 T cell activation by
T cells are antigen presentation and cytokine secretion.
Since B cells stimulated with pLAg did not produce any
significant amount of 13 cytokines that are prominent in
antigen induced recall responses, our data strongly sug-
gest that presentation of L. panamensis antigens by B
cells is responsible for CD4 T cell activation. B cells can
encounter soluble antigen soon after its entry into the
body by several mechanisms and internalize it efficiently
by BCR-mediated endocytosis [46]. Therefore, the fact
that B cells are not phagocytic cells, and thus not a nat-
ural cellular host for Leishmania, does not diminish the
relevance of their CD4 T cell activation function in CL.
Figure 5 B cells upregulate CD86 in the presence of CD4 T cells. B cells and CD4 T cells were purified from PBMCs of CL patients (n = 10),
incubated for 5 days separately or together, with or without promastigote L. panamensis antigen (pLAg), and stained for CD20, CD86, CD80, and
HLA-DR. A. Expression of CD86 within the CD20+ gate. B. Expression of CD80 within the CD20+ gate. C. Expression of HLA-DR within the CD20+
gate. *p < 0.05, **p < 0.01.
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Figure 6 Stimulation with pLAg induces cytokine secretion in B cell/CD4 T cell co-cultures from CL patients. B cells and CD4 T cells were
purified from PBMCs of CL patients (n = 10), incubated for 5 days separately or together, with or without promastigote L. panamensis antigen
(pLAg) and the indicated cytokines were measured in supernatants with a bead-based assay. *p < 0.05, **p < 0.01.
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On the contrary, this characteristic may be crucial for
their role as APCs in this disease since processing and
presentation of particulate antigens on MHCII requires
phagosome maturation, a process that can be inhibited
by Leishmania [47], whereas presentation of soluble an-
tigens on MHCII requires their correct targeting by the
endocytic receptor, a process that is highly efficient after
BCR-mediated endocytosis [30,48]. Accordingly, a study
by Carvalho et al. found that DCs that were infected by
L. braziliensis did not upregulate costimulatory and
MHCII molecules, while bystander DCs were activated
and presented soluble antigen efficiently [18]. An earlier
study by Fruth et al. also showed that infection of macro-
phages with L. major inhibited APC function, but pulsing
with Leishmania antigens did not [9]. Consequently, since
infection of APCs with live parasites inhibits their func-
tion, APCs such as B cells that do not harbor the parasite
and are capable of handling soluble antigens may be
ideally poised to activate the immune response.
Cultures of purified lymphocytes from CL patients also
showed a small but significant increase in the expression of
CD25 and CD69 and in the frequency of CD25hiCD127−
cells among CD4 T cells when these cells were co-cultured
with B cells in the absence of pLAg (Figure 4B-D). We also
found a significant induction of CD86 and HLA-DR in B
cells under the same conditions (Figure 5A and C). These
results suggest that non-cognate interactions between B
cells and CD4 T cells can generate activating signals in this
setting. The induction of homeostatic lymphocyte prolifer-
ation by MHCII/self-peptide presented by APCs is well
documented [32,49,50]. Hence, the activation observed in
B cell/CD4T cell cultures in the absence of antigen may
represent this type of interaction. Alternatively, the activa-
tion found in the absence of added antigen may be due to
B cells from infected individuals already being loaded with
Leishmania antigens, since we have found evidence of par-
asites in blood, during active CL and even after treatment
of the disease [51].
Treatment with L. panamensis upregulates MHCII and
costimualtory molecules independently of BCR signaling
and enhances BCR-mediated endocytosis in human B cells
BCR mediated endocytosis is one of the key processes that
allow B cells to become potent APCs. Therefore, we next
evaluated whether L. panamensis antigen enhances this
process. For this purpose, we used a model in which both
antigen and B cells would interact in a uniform manner.
Since the number and specificity of B cells primed by Leish-
mania infection in vivo are uncertain, we did not use pri-
mary cells from CL patients. Rather, we used Ramos cells, a
human B cell line derived from a lymphoma that expresses
surface IgM not specific for Leishmania antigens. We first
evaluated if upregulation of costimulatory and MHC mole-
cules could be achieved after treating Ramos cells with
pLAg. Because Ramos cells express TLR9, we used CpG as
a positive control of a BCR-independent activation signal.
We found that the pLAg at the 0.2 parasites:1 cell ratio we
used in cultures of primary cells did not induce a detectable
response (data not shown). To detect a significant effect,
we had to increase the parasite antigen concentration 50-
fold. At a ratio of 10 parasites:1 cell, increased expression of
CD86, CD80 and HLA-DR was observed after 48 hours of
culture to levels comparable to those induced by CpG
(Figure 7A and B). Thus, L. panamensis antigen can induce
upregulation of activation markers in Ramos cells without
BCR engagement.
To test the effect of L. panamensis antigen on BCR-
mediated endocytosis in Ramos cells, we targeted the
model antigen ovalbumin (Ova) to the BCR using an
anti-IgM antibody. BCR-mediated endocytosis of fluor-
escent Ova was evaluated in cells previously cultured for
48 hours with pLAg or CpG or without stimulus, as de-
scribed in Materials and Methods. We found that Ova
endocytosis by Ramos cells increased over the first two
hours and then reached a plateau. When these cells were
treated with CpG or pLAg, Ova endocytosis was more
efficient and continued to increase throughout the
period of evaluation (Figure 7C and D). A statistically
significant difference was detected for both pLAg and
CpG when compared to untreated cells both with re-
spect to fluorescence intensity and the percentage of
Ova-FITC positive cells at the 1 hour time point
(Figure 7E). When OVA antigen was not targeted to
the BCR, fluorescence did not increase at any time
point, confirming that the assay evaluated BCR-
mediated endocytosis (Figure 7D). This experimental
strategy allowed us to show that L. panamensis antigen
promotes specific antigen uptake by human B cells.
The expression of surface IgM did not change signifi-
cantly after treatment with CpG or pLAg (data not
shown), indicating that the enhanced endocytosis was not
due to the availability of more internalizing receptors.
Similar enhancement of Ova endocytosis was previously
observed in DCs incubated with L. braziliensis antigens
for four days [18].
These results demonstrate that L. panamensis antigen
can induce activation of B cell antigen presenting function
without BCR engagement. TLR9 is the innate immune re-
ceptor that has the highest expression on human B cells
[52-54] and it can be stimulated by Leishmania DNA
[55,56]. Since the pLAg preparation includes the parasite
DNA, it is likely that TLR9 signaling can mediate activation
of the antigen presenting function of human B cells, a ques-
tion that we will address in future studies. In humans, B
cells and plasmacytoid DCs are the only cell types respon-
sive to TLR9 [57,58]. Because the antigen presenting cap-
acity of plasmacytoid DCs is low [59] and is further
downregulated by TLR9 signaling [60], B cells constitute
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the primary APC targeted by TLR9 ligands in humans. In
light of the numerous examples of successful protection in
animals using CpG as adjuvant in vaccination strategies for
CL [61-64], defining the role of TLR9 in B cell antigen pres-
entation is critical to develop efficient strategies that can be
translated into clinical applications.
Conclusions
We have shown that B cells from the peripheral blood of
CL patients are capable of inducing CD4 T cell activa-
tion and cytokine secretion, an effect likely mediated by
antigen presentation. The CD4 T cell activating capacity
of these B cells was similar in both quantity and quality
to that observed after incubation with all cells present in
PBMCs. These B cells represent an attractive target for
immunomodulatory strategies that aim to redirect the
host’s immune response to a healing phenotype in
chronic Leishmania (Viannia) infections.
Abbreviations
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Figure 7 L. panamensis upregulates costimulatory and MHC molecules and enhances BCR-mediated endocytosis in Ramos cells. Ramos
cells were cultured without stimulus or treated with CpG or promastigote L. panamensis antigen (pLAg) for 48 hours and then incubated with
anti-IgM-biotin at 4°C and Ova-FITC-anti-biotin at 37°C for up to 3 hours. A. Expression of CD86, CD80 and HLA-DR after 48 hours of treatment.
B. Means ± SD of four experiments are shown. C. FACS analysis of the frequency of Ova-FITC positive cells after 1 hour of endocytosis.
Representative plots for one experiment are shown. D. Mean fluorescence intensity (MFI) for Ova-FITC in Ramos cells after 5, 10, 15, 30, 60, 120
and 180 minutes of endocytosis. One representative experiment of two is shown. E. Frequency of cells positive for Ova-FITC after 1 hour of
endocytosis. Means ± SD of four experiments are shown. *p < 0.05; **p < 0.01; ***p < 0.001.
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